Business
Vivani Medical to Present at the American Association of Pharmaceutical Scientists’ “Beyond GLP1s: Where the Science will Take Business Next” Virtual Workshop
ALAMEDA, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, Ph.D., will present and participate in a panel discussion at the American Association of Pharmaceutical Scientists’ (AAPS) “Beyond GLP1s: Where the Science will Take Business Next” Virtual Workshop, taking place from May 13-14, 2025. Presentatio
About this update from Vivani Medical, Inc.
[{"type":"image","alt":"Vivani Medical, Inc.","displaySize":"","headline":null,"caption":"Vivani Medical, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/c23870f4ae46a8fd33cfe7a0a48ef637"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/aU1HV9H8XgPgL8OdypT.mA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c23870f4ae46a8fd33cfe7a0a48ef637","width":300,"height":300}},"lazy":false},{"type":"text","content":"ALAMEDA, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, Ph.D., will present and participate in a panel discussion at the American Association of Pharmaceutical Scientists’ (AAPS) “Beyond GLP1s: Where the Science will Take Business Next” Virtual Workshop, taking place from May 13-14, 2025.","length":488,"tagName":"p"},{"type":"text","content":"Presentation details are as follows:","length":36,"tagName":"p"},{"type":"text","content":"Presentation: Addressing Patient Adherence: Advances in Drug DeliveryDate: Wednesday, May 14, 2025Time: 11:15 am, Eastern Time","length":128,"tagName":"p"},{"type":"text","content":"Dr. Mendelsohn will discuss Vivani's miniature drug implants that aim to improve chronic disease treatment, leveraging the company’s proprietary NanoPortal™ technology. Vivani’s lead program, NPM-115, is a six-month GLP-1 (exenatide) implant for weight management. Results from LIBERATE-1™, the first human study of NPM-115, are expected this year. These long-lasting implants are designed to improve poor medication adherence and potentially patient tolerability.","length":473,"tagName":"p"},{"type":"text","content":"Panel DiscussionPanel Date: Wednesday, May 14, 2025Panel Time: 2:00 pm, Eastern Time","length":86,"tagName":"p"},{"type":"text","content":"Dr. Mendelsohn will be joined by other industry experts in a panel discussion of the key hurdles and trends in the development of modalities in the GLP-1 drug class.","length":165,"tagName":"p"},{"type":"text","content":"More information about the AAPS workshop can be found at https://www.aaps.org/aaps/education-and-research/workshops/diabetes-drug-de...